B-cell-directed therapy: which B cells should be targeted and how?
Takashi
T
Yamamura
Sachiko
S
Miyake
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018941:Antigens, CD19 / Q000276:immunology / Q000378:metabolism; D018951:Antigens, CD20 / Q000276:immunology / Q000378:metabolism; D051401:Aquaporin 4 / Q000276:immunology; D001323:Autoantibodies / Q000378:metabolism; D001324:Autoantigens / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D008212:Lymphocyte Depletion; D009471:Neuromyelitis Optica / Q000188:drug therapy* / Q000276:immunology; D054448:Precursor Cells, B-Lymphoid / Q000187:drug effects / Q000276:immunology*; D019947:Receptors, Interleukin-6 / Q000276:immunology; D000069283:Rituximab
D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018941:Antigens, CD19; D018951:Antigens, CD20; D051401:Aquaporin 4; D001323:Autoantibodies; D001324:Autoantigens; D019947:Receptors, Interleukin-6; D000069283:Rituximab; C502936:tocilizumab